Abstract
Objective: To develop a Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) method for Leflunomide using rapid, cheap, economical, and less composition of the mobile phase. To validate the method's specificity, linearity, precision, accuracy, robustness, and ruggedness were all validated as per regulatory requirements ICH Q2 [R1] guidelines.
Methods: The method employed solving of Development and validation based on the measurement of absorbance at one wavelength, 251 nm, λ max, Inertsil-ODS C18 analytical column (250 x 4.6 mm, 5μ). 1.0 ml/min of a mobile phase consisting of water and methanol (40:60v/v) for Leflunomide tablet formulation.
Results: The method showed excellent linear response with correlation coefficient (R2) values of 0.999 for a Leflunomide. The percent recoveries for a drug were found within the acceptance limit of (99.93%–100.34%). Intra-and inter-day precision studies of the new method were less than the maximum allowable limit percentage of relative standard deviation (%RSD) ≤ 2.0. It can be concluded from the results that the present method for validation determination of Leflunomide in tablets is specific, rapid, and simple with good sensitivity.
Conclusion: This analytical method is also applicable in ordinary laboratories and also technique may be used to measure the drug and assess the uniformity and purity of the dosage formulation as well as for quality control of commercial Leflunomide tablets.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmaceutical Science,Pharmacology
Reference38 articles.
1. Srinivas RV, Narasimha RM, Allam AR, Maheswari I, Srinubabu G. Development and validation of LC method for the determination of leflunomide in pharmaceutical formulations using an experimental design. Afr J Pure Appl Chem 2008;2(2):10-7.
2. Rastogi RP, Mehrotra BN. Compendium of Indian medicinal plants. Vol. 2. Lucknow and New Delhi: Central Drug Research Institute and National Institute of Science Communication; 1980. p. 473-5.
3. Schiff MH, Whelton A. editors. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2000;30(3):196-208. doi: 10.1053/sarh.2000.16641, PMID 11124283.
4. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47(2-3):273-89. doi: 10.1016/s0162-3109(00)00191-0, PMID 10878294.
5. Viviano KR. Pharmacotherapeutics of immune‐mediated disease. Pharmacother Vet Dispensing. 2019:339-60.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献